2025 <scp>ACCP</scp> Annual Meeting Abstracts

Introduction: Postpartum anemia (PPA) affects at least 50% of women worldwide and is primarily caused by iron deficiency and blood loss during and after childbirth.Iron sucrose is a commonly used IV iron replacement therapy, often administered off-label for PPA.As with other IV iron products, iron sucrose carries the risk of hypersensitivity and cutaneous reactions, including pruritus, pain, and erythema.Research Question or Hypothesis: What is the incidence of cutaneous drug reactions with intravenous (IV) push iron sucrose in patients with PPA? Study Design: Institutional Review Board-approved, single center, retrospective chart review.Methods: Postpartum patients who received IV push iron sucrose between January and October 2024 were assessed for cutaneous reactions.Patients who received iron sucrose infusions via infusion were excluded.Data collected included demographics, iron sucrose dose, IV-gauge, reaction type, and treatment.The primary endpoint was incidence of cutaneous reactions during and after administration.Results: The electronic medical record identified 337 patients who received IV iron sucrose administered via IV push.Among these patients, 31 (9%) were recorded to have had a cutaneous reaction to iron sucrose.The most frequently observed reaction was infiltration, which occurred in 51% of affected patients.Other symptoms included swelling, pain, and erythema.Of these 31 patients, 74% required no intervention, 22% required nonpharmacological treatment, and 3% required pharmacologic intervention.The mean gauge size was 18 in both patients with and without cutaneous reactions.Conclusion: Based on the findings, IV iron sucrose may be administered via IV push as incidence of cutaneous reactions was less than 10%.Clinical staff should receive additional training on the potential for cutaneous reactions and the importance of documentation.For patients with a history of reactions to IV iron, administration via infusion rather than IV push is advised to minimize risk.Additional cohort studies are warranted to further evaluate the incidence of cutaneous reactions associated with iron sucrose.